Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2015 16:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentation at the UBS 2015 Global Healthcare Conference

CAMBRIDGE, Mass., May 12, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
May 06, 2015 16:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch 2015 Health Care Conference

CAMBRIDGE, Mass., May 6, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
May 01, 2015 16:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 40th Annual Health Care Conference

CAMBRIDGE, Mass., May 1, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
May 01, 2015 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Reports First Quarter 2015 Financial Results

CAMBRIDGE, Mass., May 1, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2015. For the first quarter...
April 20, 2015 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Presents Key Glatopa(TM) (glatiramer acetate injection) Data at American Academy of Neurology Annual Meeting

CAMBRIDGE, Mass., April 20, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
April 17, 2015 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Data Presentations on Glatopa(TM) (glatiramer acetate injection) at the American Academy of Neurology's (AAN) 2015 Annual Meeting

CAMBRIDGE, Mass., April 17, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
April 16, 2015 12:53 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA Approval for Glatopa(TM) (glatiramer acetate injection)

CAMBRIDGE, Mass., April 16, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
April 16, 2015 12:30 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg

First generic multiple sclerosis product approved in the United States Approval triggers $10 million milestone payment to Momenta CAMBRIDGE, Mass., April 16, 2015 (GLOBE NEWSWIRE) --...
April 15, 2015 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Date of First Quarter 2015 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., April 15, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
March 02, 2015 15:34 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Publication Revealing Development of a Novel Process to Generate High-Quality Hyper-sialylated IVIg Drug Candidate in PNAS

CAMBRIDGE, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...